CVT-2551

• CAT Number: I006320
• CAS Number: 172430-44-3
• Molecular Formula: C24H33N3O5
• Molecular Weight: 443.54
• Purity: ≥95%
• Synonyms: CVT-2551; CVT 2551; CVT2551; RS-89961; UNII-ZV6358217Q.;1-Piperazineacetamide, 4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-N-(2-(hydroxymethyl)-6-methylphenyl)-
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4°C for short term ,or -20 °C for long term
• IUPAC Name: 2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]-N-[2-(hydroxymethyl)-6-methylphenyl]acetamide
• InChI: InChI=1S/C24H33N3O5/c1-18-6-5-7-19(16-28)24(18)25-23(30)15-27-12-10-26(11-13-27)14-20(29)17-32-22-9-4-3-8-21(22)31-2/h3-9,20,28-29H,10-17H2,1-2H3,(H,25,30)
• InChIKey: OMMZXYCXHPSQGB-UHFFFAOYSA-N
• SMILES: CC1=C(C(=CC=C1)CO)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O

CVT-2551（Cat No.:I006320）is an experimental small molecule that acts as a selective inhibitor of the enzyme phosphodiesterase 10A (PDE10A). PDE10A is primarily expressed in the brain, particularly in the striatum, and plays a key role in regulating dopamine signaling. By inhibiting PDE10A, CVT-2551 enhances dopaminergic activity, which may have therapeutic implications for neuropsychiatric disorders like schizophrenia, Parkinson’s disease, and Huntington’s disease. Preclinical studies suggest that CVT-2551 could improve cognitive function and motor symptoms. However, more clinical research is needed to determine its safety and efficacy in humans.